Literature DB >> 12706956

Comorbidity and depression treatment.

K Ranga Rama Krishnan1.   

Abstract

Comorbidity is common among patients with major depression, but in most instances it may be of little relevance. Nonetheless, it is a complex issue because of its relation to treatment response, and few studies have attempted to address this. Most have examined comorbidity after the fact in secondary analyses. In this article, I focus on whether comorbidity influences depression treatment response among patients who are primarily diagnosed as suffering from major depression. At least three comorbidities are believed to influence treatment response: medical, anxiety, and personality disorders. Whether studies find that these factors predict worse outcomes in patients with major depression appears to depend on the nature and severity of the medical illness, the study setting, and the study design. The best designed studies reported the least effects of these factors on treatment outcome. Clinically, this suggests that these factors should not be seen as impediments to treatment. Copyright 2003 Society of Biological Psychiatry

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706956     DOI: 10.1016/s0006-3223(02)01787-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

1.  Pharmacotherapy of anxious depression.

Authors:  Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

2.  Comorbid chronic illness and the diagnosis and treatment of depression in safety net primary care settings.

Authors:  Chizobam Ani; Mohsen Bazargan; David Hindman; Douglas Bell; Michael Rodriguez; Richard S Baker
Journal:  J Am Board Fam Med       Date:  2009 Mar-Apr       Impact factor: 2.657

3.  Major depressive disorder and medical illness: STAR*D outcomes.

Authors:  Prakash Masand; Meera Narasimhan
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

4.  Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study.

Authors:  Elena Di Nasso; Alberto Chiesa; Alessandro Serretti; Diana De Ronchi; Claudio Mencacci
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

5.  Neonatal intramuscular injection of plasmid encoding glucagon-like peptide-1 affects anxiety behaviour and expression of the hippocampal glucocorticoid receptor in adolescent rats.

Authors:  Huitao Fan; Lina Wang; Feng Guo; Shi Wei; Ruqian Zhao
Journal:  J Biosci       Date:  2010-03       Impact factor: 1.826

6.  Depressed adolescents and comorbid psychiatric disorders: are there differences in the presentation of depression?

Authors:  David Marc Small; Anne D Simons; Paul Yovanoff; Susan G Silva; Cara C Lewis; Jessica L Murakami; John March
Journal:  J Abnorm Child Psychol       Date:  2008-05-29

7.  Predictors of treatment outcomes among depressed women with childhood sexual abuse histories.

Authors:  Natalie A Cort; Stephanie A Gamble; Phillip N Smith; Linda H Chaudron; Naiji Lu; Hua He; Nancy L Talbot
Journal:  Depress Anxiety       Date:  2012-05-08       Impact factor: 6.505

8.  Neurofilament Light Chain Is a Novel Biomarker for Major Depression and Related Executive Dysfunction.

Authors:  Mu-Hong Chen; Yu-Li Liu; Hsiang-Wei Kuo; Shih-Jen Tsai; Ju-Wei Hsu; Kai-Lin Huang; Pei-Chi Tu; Ya-Mei Bai
Journal:  Int J Neuropsychopharmacol       Date:  2022-02-11       Impact factor: 5.176

9.  Racial and Ethnic Disparities in Treatment and Treatment Type for Depression in a National Sample of Medicaid Recipients.

Authors:  Brian McGregor; Chaohua Li; Peter Baltrus; Megan Douglas; Jammie Hopkins; Glenda Wrenn; Kisha Holden; Ebony Respress; Anne Gaglioti
Journal:  Psychiatr Serv       Date:  2020-04-02       Impact factor: 3.084

Review 10.  Incomplete remission in depression: role of psychiatric and somatic comorbidity.

Authors:  Christian Otte
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.